Pharming Group N.V. (PHAR)
NGM – Real vaqt narxi. Valyuta: USD
13.09
+0.47 (3.69%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Find any stock by ticker or company name

NGM – Real vaqt narxi. Valyuta: USD
13.09
+0.47 (3.69%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Pharming Group N.V., bir biopharmaceutical kompaniyasi, AQSh, Yevropa va xalqaro miqyosda noyob kasalliklarni davolash uchun oqsil almashtirish terapiyalari va aniq dori vositalarini ishlab chiqadi va tijoratlashtiradi. Kompaniyaning asosiy mahsuloti RUCONEST, o'tkir irsiy angioedema (HAE) ning o'tkir hujumlarini davolash uchun rekombinant C1 esteraza ingibitori; va Joenja (leniolisib), faollashgan fosfoinozitid 3-kinaza delta sindromini davolash uchun og'iz orqali qabul qilinadigan kichik molekula PI3Kẟ ingibitori. Shuningdek, u Joenja, og'iz orqali qabul qilinadigan kichik molekula PI3Kẟ ingibitorini ishlab chiqadi. U Novartis bilan rivojlanish hamkorligi va litsenziya shartnomasiga ega. Pharming Group N.V. 1988 yilda tashkil etilgan va Gollandiyaning Leyden shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Alexander Breidenbach M.B.A. | Chief Business Officer |
| Dr. Anurag Relan M.D., MPH | Chief Medical Officer |
| Dr. Magnus Hansson | Medical Director |
| Mr. Fabrice Chouraqui Ph.D., Pharm.D. | CEO & Executive Director |
| Mr. Kenneth Lynard EMBA | Chief Financial Officer |
| Mr. Michael K. Levitan | VP of Investor Relations & Corporate Communications |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 6-K | pharminggroupannouncespres.htm |
| 2026-04-16 | 6-K | pharminggroupannouncesthe2.htm |
| 2026-04-13 | 20-F/A | pharm-20251231.htm |
| 2026-04-02 | 6-K | pharminggroupannouncesthef.htm |
| 2026-04-02 | 20-F | pharm-20251231.htm |
| 2026-03-27 | 6-K | pharminggroupreceivesposit.htm |
| 2026-03-24 | 6-K | pharminggroupannouncesappr.htm |
| 2026-03-12 | 6-K | a2025q4pressrelease.htm |
| 2026-02-03 | 6-K | pharminggroupannounces2026.htm |
| 2026-02-02 | 6-K | pharminggroupreceivescompl.htm |
| Mr. Ruud Van Outersterp | Chief Legal & Compliance Officer |
| Ms. Ines Bernal | Chief People Officer |
| Ms. Leverne Marsh | Chief Commercial Officer |
| Ms. Mireille Sanders M.Sc. | Chief Operations Officer |